Morningstar analyst Michael Makdad has also increased his target price to $47 from $46, implying a P/B multiple of 2 times.

Is IDEXX Laboratories a good investment? Analyzing its consistent growth, innovative products, and international expansion ...

Most readers would already know that Schwälbchen Molkerei Jakob Berz's (FRA:SMB) stock increased by 2.3% over the ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Consensus estimates expect Coke to print $0.52 in EPS, $10.68 billion in revenue and $2.67 billion in operating income, for ...

Analyst Mike Parkin: “Kinross maintains significant opportunities for growth within its North American portfolio, which should help to further improve its geopolitical risk profile. This includes the ...

Despite volatility in the broader markets, some midcap stocks have stood out with strong returns in 2025. While the Nifty ...

Citi has maintained a 'sell' rating on Nykaa, raising the target price to Rs 160 from Rs 155. Operating leverage has improved ...

The group balance sheet is strong, with Macquarie Bank having an APRA Basel III common equity Tier 1 capital ratio of 12.6% as of December 2024. At a group level, Macquarie has AUD 8.5 billion in ...

The fund management firm added that pricing power companies are often less glamorous and newsworthy, except in their early growth stages. However, they are quiet, stable, and high-quality compounders ...

RBC Capital Markets updated its outlook on CNO Financial Group (NYSE:CNO), raising the stock's price target from $40.00 to $45.00 while maintaining an Outperform rating. The stock currently trades at ...